Evolent Health (EVH) reported $468.72 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 27.5%. EPS of $0.08 for the same period compares to -$0.02 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $469.22 million, representing a surprise of -0.11%. The company delivered an EPS surprise of +28%, with the consensus EPS estimate being $0.06.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Average PMPM Fees / Revenue per Case - Performance Suite: $13.87 versus $14.14 estimated by three analysts on average. Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.40 versus $0.38 estimated by three analysts on average. Average PMPM Fees / Revenue per Case - Administrative Services: $15.27 compared to the $15.78 average estimate based on three analysts. Average Lives on Platform / Cases - Cases: 14 thousand versus 13.86 thousand estimated by three analysts on average. Average Lives on Platform / Cases - Performance Suite: 6.48 million versus the three-analyst average estimate of 6.53 million. Average Lives on Platform / Cases - Specialty Technology and Services Suite: 79.68 million compared to the 78.38 million average estimate based on three analysts. Average Lives on Platform / Cases - Administrative Services: 1.22 million versus the three-analyst average estimate of 1.2 million. Average PMPM Fees / Revenue per Case - Cases: $3,537.00 compared to the $3,142.27 average estimate based on three analysts. Total Revenue by product type- Performance Suite: $269.46 million versus $276.94 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -41% change. Total Revenue by product type- Cases: $47.71 million compared to the $43.5 million average estimate based on three analysts. The reported number represents a change of -0.5% year over year. Total Revenue by product type- Administrative Services: $55.8 million versus the three-analyst average estimate of $56.69 million. The reported number represents a year-over-year change of -5.9%. Total Revenue by product type- Specialty Technology and Services Suite: $95.74 million versus the three-analyst average estimate of $88.49 million. The reported number represents a year-over-year change of +16.3%.View all Key Company Metrics for Evolent Health here>>>
Shares of Evolent Health have returned -25.3% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Evolent Health, Inc (EVH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).